Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11

Showing 11 citing articles:

The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
Qinglong Ma, Wenyang Zhang, Kongming Wu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Cell death pathways: molecular mechanisms and therapeutic targets for cancer
Shaohui Wang, Sa Guo, Jing Guo, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access | Times Cited: 11
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 353-353
Open Access | Times Cited: 1
Targeting RAS and associated proteins
Matthias Müller, Roger S. Goody, Daniel Rauh
Elsevier eBooks (2025)
Closed Access
Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS–mutant cancer models
Shihui Shen, Qiansen Zhang, Yuhan Wang, et al.
Journal of Clinical Investigation (2025) Vol. 135, Iss. 6
Open Access
New exploration of KRASG12D inhibitors and the mechanisms of resistance
Yinghong Li, Junfeng Zhao, Yintao Li
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Zehn Jahre Molekulares Tumorboard: von der Genomsequenzierung zur personalisierten Krebstherapie
Benedikt Färber, Jan Morf, Jan Vorwerk, et al.
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie (2025) Vol. 150, Iss. 02, pp. 175-182
Closed Access
HRS-4642: The next piece of the puzzle to keep KRAS in check
Alejandra A. Flores-Gómez, Matthias Drosten
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1157-1159
Closed Access | Times Cited: 4
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC
A. Domínguez, M Perz, Yi Xu, et al.
Cancers (2024) Vol. 16, Iss. 21, pp. 3564-3564
Open Access | Times Cited: 1
Bioinspired micro‐ and nanostructured systems for cancer therapy
Ruizhen Yang, Bing Zhang, Xiawei Fei, et al.
MedComm (2024) Vol. 5, Iss. 12
Closed Access
Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges
Xin Yang, Xiang Li, Yuelin Zhang, et al.
Future Medicinal Chemistry (2024), pp. 1-5
Closed Access
Page 1

Scroll to top